Shell Asset Management CO Amicus Therapeutics, Inc. Transaction History

Shell Asset Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$9.2 - $23.86 $171,147 - $443,867	-18,603 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$8.86 - $15.69 $1,975 - $3,498	-223 Reduced 1.18%	18,603 $281,000
Q1 2020 May 11, 2020	SELL	$6.63 - $11.16 $1,896 - $3,191	-286 Reduced 1.5%	18,826 $174,000
Q4 2019 Feb 13, 2020	SELL	$7.48 - $10.75 $3,253 - $4,676	-435 Reduced 2.23%	19,112 $186,000
Q3 2019 Nov 12, 2019	SELL	$8.02 - $13.25 $1,347 - $2,226	-168 Reduced 0.85%	19,547 $157,000
Q2 2019 Aug 12, 2019	SELL	$10.96 - $14.4 $4,932 - $6,480	-450 Reduced 2.23%	19,715 $246,000
Q4 2018 Feb 13, 2019	SELL	$8.38 - $13.44 $14,246 - $22,848	-1,700 Reduced 7.77%	20,165 $193,000
Q3 2018 Nov 13, 2018	BUY	$11.6 - $16.54 $253,634 - $361,647	21,865 New	21,865 $264,000

278

324M

260K

261K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $3B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.